Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

HHS vs ICLR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
HHS
Harte Hanks, Inc.

Advertising Agencies

Communication ServicesNASDAQ • US
Market Cap$21M
5Y Perf.+21.9%
ICLR
ICON Public Limited Company

Medical - Diagnostics & Research

HealthcareNASDAQ • IE
Market Cap$9.54B
5Y Perf.-25.8%

HHS vs ICLR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
HHS logoHHS
ICLR logoICLR
IndustryAdvertising AgenciesMedical - Diagnostics & Research
Market Cap$21M$9.54B
Revenue (TTM)$160M$8.10B
Net Income (TTM)$-811K$599M
Gross Margin41.2%26.9%
Operating Margin0.7%12.2%
Forward P/E10.5x
Total Debt$22M$3.60B
Cash & Equiv.$6M$539M

HHS vs ICLRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

HHS
ICLR
StockMay 20May 26Return
Harte Hanks, Inc. (HHS)100121.9+21.9%
ICON Public Limited… (ICLR)10074.2-25.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: HHS vs ICLR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ICLR leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Harte Hanks, Inc. is the stronger pick specifically for capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
HHS
Harte Hanks, Inc.
The Income Pick

HHS is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 0.71
  • Lower volatility, beta 0.71, current ratio 1.54x
  • Beta 0.71, current ratio 1.54x
Best for: income & stability and sleep-well-at-night
ICLR
ICON Public Limited Company
The Growth Play

ICLR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 2.0%, EPS growth 28.8%, 3Y rev CAGR 14.8%
  • 91.0% 10Y total return vs HHS's -82.7%
  • 2.0% revenue growth vs HHS's -13.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthICLR logoICLR2.0% revenue growth vs HHS's -13.9%
Quality / MarginsICLR logoICLR7.4% margin vs HHS's -0.5%
Stability / SafetyHHS logoHHSBeta 0.71 vs ICLR's 1.60
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)ICLR logoICLR-10.0% vs HHS's -42.2%
Efficiency (ROA)ICLR logoICLR3.6% ROA vs HHS's -0.9%, ROIC 6.5% vs 4.4%

HHS vs ICLR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

HHSHarte Hanks, Inc.
FY 2025
Fulfillment and Logistics Services
59.8%$74M
Customer Care
40.2%$50M
ICLRICON Public Limited Company
FY 2012
Clinical Research
92.2%$1.0B
Central Laboratory
7.8%$87M

HHS vs ICLR — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLICLRLAGGINGHHS

Income & Cash Flow (Last 12 Months)

ICLR leads this category, winning 4 of 6 comparable metrics.

ICLR is the larger business by revenue, generating $8.1B annually — 50.8x HHS's $160M. ICLR is the more profitable business, keeping 7.4% of every revenue dollar as net income compared to HHS's -0.5%. On growth, ICLR holds the edge at +0.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricHHS logoHHSHarte Hanks, Inc.ICLR logoICLRICON Public Limit…
RevenueTrailing 12 months$160M$8.1B
EBITDAEarnings before interest/tax$6M$1.4B
Net IncomeAfter-tax profit-$811,000$599M
Free Cash FlowCash after capex-$4M$996M
Gross MarginGross profit ÷ Revenue+41.2%+26.9%
Operating MarginEBIT ÷ Revenue+0.7%+12.2%
Net MarginNet income ÷ Revenue-0.5%+7.4%
FCF MarginFCF ÷ Revenue-2.3%+12.3%
Rev. Growth (YoY)Latest quarter vs prior year-15.4%+0.6%
EPS Growth (YoY)Latest quarter vs prior year+190.9%-98.7%
ICLR leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

HHS leads this category, winning 4 of 4 comparable metrics.

On an enterprise value basis, HHS's 5.6x EV/EBITDA is more attractive than ICLR's 7.9x.

MetricHHS logoHHSHarte Hanks, Inc.ICLR logoICLRICON Public Limit…
Market CapShares × price$21M$9.5B
Enterprise ValueMkt cap + debt − cash$37M$12.6B
Trailing P/EPrice ÷ TTM EPS-25.27x13.12x
Forward P/EPrice ÷ next-FY EPS est.10.53x
PEG RatioP/E ÷ EPS growth rate1.87x
EV / EBITDAEnterprise value multiple5.64x7.95x
Price / SalesMarket cap ÷ Revenue0.13x1.15x
Price / BookPrice ÷ Book value/share1.00x1.09x
Price / FCFMarket cap ÷ FCF8.53x
HHS leads this category, winning 4 of 4 comparable metrics.

Profitability & Efficiency

ICLR leads this category, winning 7 of 9 comparable metrics.

ICLR delivers a 6.3% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-4 for HHS. ICLR carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to HHS's 1.09x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs HHS's 2/9, reflecting strong financial health.

MetricHHS logoHHSHarte Hanks, Inc.ICLR logoICLRICON Public Limit…
ROE (TTM)Return on equity-3.9%+6.3%
ROA (TTM)Return on assets-0.9%+3.6%
ROICReturn on invested capital+4.4%+6.5%
ROCEReturn on capital employed+3.4%+7.8%
Piotroski ScoreFundamental quality 0–927
Debt / EquityFinancial leverage1.09x0.38x
Net DebtTotal debt minus cash$17M$3.1B
Cash & Equiv.Liquid assets$6M$539M
Total DebtShort + long-term debt$22M$3.6B
Interest CoverageEBIT ÷ Interest expense0.69x3.96x
ICLR leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ICLR leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in ICLR five years ago would be worth $5,463 today (with dividends reinvested), compared to $5,388 for HHS. Over the past 12 months, ICLR leads with a -10.0% total return vs HHS's -42.2%. The 3-year compound annual growth rate (CAGR) favors ICLR at -13.0% vs HHS's -21.9% — a key indicator of consistent wealth creation.

MetricHHS logoHHSHarte Hanks, Inc.ICLR logoICLRICON Public Limit…
YTD ReturnYear-to-date-9.2%-33.7%
1-Year ReturnPast 12 months-42.2%-10.0%
3-Year ReturnCumulative with dividends-52.3%-34.1%
5-Year ReturnCumulative with dividends-46.1%-45.4%
10-Year ReturnCumulative with dividends-82.7%+91.0%
CAGR (3Y)Annualised 3-year return-21.9%-13.0%
ICLR leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — HHS and ICLR each lead in 1 of 2 comparable metrics.

HHS is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than ICLR's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICLR currently trades 59.2% from its 52-week high vs HHS's 51.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricHHS logoHHSHarte Hanks, Inc.ICLR logoICLRICON Public Limit…
Beta (5Y)Sensitivity to S&P 5000.71x1.60x
52-Week HighHighest price in past year$5.39$211.00
52-Week LowLowest price in past year$2.22$66.57
% of 52W HighCurrent price vs 52-week peak+51.6%+59.2%
RSI (14)Momentum oscillator 0–10057.062.1
Avg Volume (50D)Average daily shares traded9K1.1M
Evenly matched — HHS and ICLR each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricHHS logoHHSHarte Hanks, Inc.ICLR logoICLRICON Public Limit…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$149.63
# AnalystsCovering analysts30
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.3%+5.2%
Insufficient data to determine a leader in this category.
Key Takeaway

ICLR leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HHS leads in 1 (Valuation Metrics). 1 tied.

Best OverallICON Public Limited Company (ICLR)Leads 3 of 6 categories
Loading custom metrics...

HHS vs ICLR: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is HHS or ICLR a better buy right now?

For growth investors, ICON Public Limited Company (ICLR) is the stronger pick with 2.

0% revenue growth year-over-year, versus -13. 9% for Harte Hanks, Inc. (HHS). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate ICON Public Limited Company (ICLR) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — HHS or ICLR?

Over the past 5 years, ICON Public Limited Company (ICLR) delivered a total return of -45.

4%, compared to -46. 1% for Harte Hanks, Inc. (HHS). Over 10 years, the gap is even starker: ICLR returned +91. 0% versus HHS's -82. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — HHS or ICLR?

By beta (market sensitivity over 5 years), Harte Hanks, Inc.

(HHS) is the lower-risk stock at 0. 71β versus ICON Public Limited Company's 1. 60β — meaning ICLR is approximately 125% more volatile than HHS relative to the S&P 500. On balance sheet safety, ICON Public Limited Company (ICLR) carries a lower debt/equity ratio of 38% versus 109% for Harte Hanks, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — HHS or ICLR?

By revenue growth (latest reported year), ICON Public Limited Company (ICLR) is pulling ahead at 2.

0% versus -13. 9% for Harte Hanks, Inc. (HHS). On earnings-per-share growth, the picture is similar: Harte Hanks, Inc. grew EPS 97. 3% year-over-year, compared to 28. 8% for ICON Public Limited Company. Over a 3-year CAGR, ICLR leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — HHS or ICLR?

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus -0. 5% for Harte Hanks, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICLR leads at 13. 3% versus 1. 4% for HHS. At the gross margin level — before operating expenses — ICLR leads at 29. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — HHS or ICLR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is HHS or ICLR better for a retirement portfolio?

For long-horizon retirement investors, Harte Hanks, Inc.

(HHS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). ICON Public Limited Company (ICLR) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HHS: -82. 7%, ICLR: +91. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between HHS and ICLR?

These companies operate in different sectors (HHS (Communication Services) and ICLR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HHS is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

HHS

Quality Business

  • Sector: Communication Services
  • Market Cap > $100B
  • Gross Margin > 24%
Run This Screen
Stocks Like

ICLR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform HHS and ICLR on the metrics below

Revenue Growth>
%
(HHS: -15.4% · ICLR: 0.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.